Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lung transplant rejection diagnosis gets a molecular makeover

NCT ID NCT02812290

Knowledge-focused Sponsor: University of Alberta Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at lung transplant biopsies to see if molecular testing can better diagnose rejection. Researchers will collect biopsy samples from 700 lung transplant recipients and analyze them using a molecular classifier. The goal is to improve accuracy and potentially develop a safer biopsy method.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to more accurate and safer ways to diagnose lung transplant rejection, potentially reducing the need for invasive biopsies.
What could go wrong
This is an observational study, not a treatment trial. It may not directly improve patient outcomes, and the molecular tests might not prove better than current methods.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 700 people

The number the study aims to enrol. It can still change while the study runs.

Start date

May 2016

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with functioning lung transplant biopsied to determine their graft dysfunction or to confirm good function as per standard of care.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * All lung transplant recipients undergoing a biopsy as determined by their surgeon or physician. Exclusion Criteria: * Patients who declined participation or unable to give informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lung transplant rejection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

transplant rejection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lung transplant rejection

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites in 3 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Alberta Transplant Applied Genomics Centre, University of Alberta

    RECRUITING

    Edmonton, Alberta, T6G 2E1, Canada

  • Charles University/Hospital Motol

    RECRUITING

    Prague, Czechia

  • Department of Medicine, University of Alberta

    RECRUITING

    Edmonton, Alberta, T6G 2G3, Canada

  • Department of Thoracic Surgery, Medical University of Vienna

    COMPLETED

    Vienna, Austria

  • Division of Pulmonary and Critical Care, Washington University School of Medicine

    COMPLETED

    St Louis, Missouri, 63110, United States

  • St. Joseph's Hospital and Medical Center 350 West Thomas Road, Floor 8HLT

    RECRUITING

    Phoenix, Arizona, 85013, United States

  • The Alfred Hospital, Monash University

    COMPLETED

    Melbourne, Australia

  • Thoracic Surgery Transplant Clinic

    COMPLETED

    Szczecin, 70891, Poland

  • University Health Network, Toronto General Hospital

    COMPLETED

    Toronto, Ontario, M5G 2C4, Canada

  • University of Maryland School of Medicine

    COMPLETED

    Baltimore, Maryland, 21201, United States

  • University of Texas at San Antonio

    COMPLETED

    San Antonio, Texas, 21201, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.